Oyster Point Pharmaceuticals
San Francisco
About Oyster Point Pharmaceuticals
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $235.8M
- Funding stage: M&A
- Last round: Post-IPO Equity (May 2020)
- Ticker: nasdaq:OYST
- Website: oysterpointrx.com
- Phone: [email protected]
Industries & Categories
Biopharma, Clinical Trials, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/oyster-point-pharmaceuticals-88968 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.